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Background: There is evidence to suggest the existence of an executive 
dysfunction in people diagnosed with fibromyalgia, although there are certain 
inconsistencies between studies. Here, we aim to compare executive performance 
between patients with fibromyalgia and a control group by using subjective and 
objective cognitive tests, analysing the influence of patient mood on the results 
obtained, and studying associations between the two measures. Method: 82 
patients diagnosed with fibromyalgia and 42 healthy controls, matched by age 
and years of education, were assessed using BRIEF-A
1
 as a subjective measure of 
executive functioning. A selection of objective cognitive tests were also used to 
measure a series of executive functions and to identify symptoms of depression 
and anxiety. Results: Patients with fibromyalgia perceived greater difficulties 
than the control group on all of the BRIEF-A scales. However, after adjustments 
were made for depression and anxiety the only differences that remained were 
those associated with the working memory scale and the Metacognition and 
Global Executive Composite index. In the case of the objective cognitive tests, a 
significantly worse overall performance was evidenced for the fibromyalgia 
patients. However, this also disappeared when adjustments were made for 
depression and anxiety. After this adjustment, fibromyalgia patients only 
performed significantly worse for the interference effect in the Stroop Test. 
Although there were no significant associations between most of the objective 
cognitive tests and the BRIEF-A scales, depression and anxiety exhibited strong 
associations with almost all of the BRIEF-A scales and with several of the 
objective cognitive tests. Conclusions: Patients with fibromyalgia showed 
executive dysfunction in subjective and objective measures, although most of this 
impairment was associated with mood disturbances. Exceptions to this general 
rule were observed in the impairment of working memory evidenced on the 
BRIEF-A scale and the inhibition impairment exhibited by the interference effect 
from the Stroop Test. The two types of measurement provide different yet 
complementary information. 
Keywords: Fibromyalgia; executive functions; subjective cognitive dysfunction; 
depression; anxiety. 
 
1. Introduction 
 
                                                 
1
 Behavioral Rating Inventory of Executive Function – Adult version  
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 Fibromyalgia is a chronic disease belonging to the group of musculoskeletal 
diseases. It is characterized by the presence of generalized and diffuse pain, which is 
generally accompanied by other symptoms such as fatigue, restless sleep, depression 
and cognitive disorders [1]. Although pain is the main symptom of this disease, 
cognitive complaints are common in affected patients and contribute to an increased 
perception of disability and to this disease having a great impact on the quality of life of 
these patients [2].  
 
The study of cognitive complaints associated with this disease has gained 
interest in recent years. These are now recognized as components of an independent 
symptom which must be studied as it causes patients increased suffering and discomfort 
[3]. Several studies have coincided in identifying the existence of cognitive dysfunction 
in fibromyalgia and in emphasizing problems associated with executive functions and, 
more specifically, with working memory processes and attentional and executive 
control [4–7]. However, some authors have failed to find such impaired performance in 
these components [8–10], while others have even concluded that the cognitive 
dysfunction observed in these patients could be explained by concurrent symptoms of 
depression [11,12]. 
 
 The executive functions construct  includes an extensive variety of cognitive 
processes including: inhibition, impulse control, working memory, affect regulation, 
motivation, planning, organization, decision-making, judgment, monitoring, problem-
resolution, hypothesis generation, abstract thought and cognitive flexibility [13,14]. 
Research on executive functions has linked the presence of executive dysfunction to 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
performance in day-to-day activities and shown that executive dysfunction may 
significantly contribute to functional difficulties [15,16].  
 
  Executive functions have traditionally been assessed through the use of objective 
cognitive tests, with this requiring the breakdown of these executive functions into their 
different cognitive processes in order to identify which have been conserved and which 
have been impaired. However, in clinical practice, it has been shown that the 
breakdown of this complex cognitive process is artificial. Studies performed with 
patients suffering from neurological conditions have revealed that objective cognitive 
tests of executive performance largely fail to collect the integrated, multidimensional, 
priority-based decision-making that is often demanded in real world situations, exhibit 
poor ecologic validity, and do not identify executive disorders in day-to-day functioning 
[17–24]. However, another way to evaluate executive functions is through daily 
functioning questionnaires; these are subjective evaluations that are usually 
administered to patients, and/or their relatives, and that have shown greater sensitivity 
than objective cognitive tests for reflecting everyday situations. In fact, subjective and 
objective measurements of executive functions seem to evaluate different processes: 
objective cognitive tests may assess underlying executive abilities, while the daily 
functioning questionnaires assess the application of these abilities in daily life [25]. 
 One daily functioning questionnaire that has acquired significant importance in 
recent years is the Behavior Rating Inventory of Executive Function – Adult Version 
(BRIEF-A) [26], which measures problems in executive functions. This is a subjective 
measure, as it uses self-reported information to assess the impact of an individual’s 
perceived executive functioning on their day-to-day behavior. The inventory has been 
validated in an extensive variety of populations and has shown a number of good 
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psychometric properties. Studies using this scale have shown that it offers a useful way 
to assess and detect executive dysfunction in patients with ADHD, schizophrenia, mild 
cognitive impairment, traumatic brain injury, hypersexuality and eating disorders, and 
in those who are pathological gamblers and ecstasy consumers, among others [14,27–
33]. 
 
 Our primary aim was to determine whether there were significant differences 
between patients suffering from fibromyalgia and controls with respect to a series of 
subjective and objective measures of executive functions and then to analyse the 
influence of patient mood on performance in certain specific measures. We were also 
interested in exploring associations between the different components of the subjective 
and objective measures used in the study in order to understand the relationships 
between them and to know whether both approaches could be applied to provide useful 
and complementary information. Our hypothesis was that patients with fibromyalgia 
would perform significantly worse than the control group in subjective and objective 
tests of executive functions and that mood symptoms would exhibit associations with 
the performance of both measurement strategies. We also hypothesized that we would 
find a lack of significant associations between subjective and objective measures. 
 
1. Method 
2.1. Participants 
 We carried out a cross-sectional, case-control observational study in which we 
invited 100 patients who had been diagnosed with fibromyalgia to participate. Of these, 
18 were excluded (3 decided not to participate, 7 were ineligible because they did not 
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meet the entry criteria and another 8 subsequently revoked their consent). Our sample 
population finally consisted of 82 women diagnosed with fibromyalgia who were 
recruited from the Fibromyalgia Unit of the Hospital Santa Maria of Lleida and who 
met the classification criteria of the American College of Rheumatology (Wolfe et al. 
1990). Recruitment was performed between August 2012 and November 2014. The 
exclusion criteria were: (a) a history of neurological disorders; (b) a history of 
diagnosed psychotic spectrum; (c) a current major depressive episode; (d) a history of 
dependence on psychoactive substances; (e) a low estimated IQ, with a standard score 
of less than 85 according to the Vocabulary subtest of the Wechsler Adult Intelligence 
Scale (3
rd
 edition), WAIS-III [34]; (f) ongoing treatment with antipsychotic drugs, (g) 
cognitive global impairment at the dementia level, with a score of ≤24 on the Mini 
Mental State Examination [35]; and (h) the diagnosis of other chronic autoimmune 
rheumatic diseases. The control group consisted of 42 healthy female volunteers who 
were recruited from non-healthcare community settings and matched with the patient 
group by age and years of education at a ratio of 2:1. The exclusion criteria were the 
same as for the patient group, with the addition of the presence of any rheumatologic 
diagnosis and also of any psychiatric disease. The study was approved by the hospital’s 
institutional ethics committee (Hospital Universitari Arnau de Vilanova – CEIC 1068) 
and the research was carried out in accordance with the Helsinki Declaration. Written 
informed consent was obtained from each participant prior to their participation in the 
study.  
 
1.2. Clinical Measures 
1.2.1. Subjective Assessment of Executive Function 
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 A subjective assessment of problems of executive functions was conducted by 
applying the BRIEF-A scale, which is a self-administered, standardized questionnaire 
whose aim is to identify problems in everyday life that can be attributed to executive 
dysfunction [26]. BRIEF-A provides a combined score for executive function, the 
Global Executive Composite (GEC) and two indices: the Behavioral Regulation Index, 
which includes four subscales (Inhibit, Shift, Emotional Control and Self-monitor), and 
the Metacognition Index, which includes five subscales (Initiate, Working Memory, 
Plan/Organize, Self-monitor and Organization of Materials). This questionnaire also 
includes 3 validity scales that indicate whether respondents tend: to have an unusually 
negative response style (Negativity scale); to report highly unusual symptoms 
(Infrequency scale); or to answer similar items in an inconsistent manner (Inconsistency 
scale). A Negativity scale raw score of 6 or higher indicates a high degree of negativity, 
an Infrequency scale raw score of 3 or higher evidences atypical responses, and an 
Inconsistency scale score of 8 or higher suggests the presence of inconsistent responses. 
The BRIEF-A scale uses T scores for which the mean value for the normative 
population is fixed at 50, the standard deviation is 10, and higher scores indicate worse 
performances.  
 
1.2.2. Objective Cognitive Assessment 
 For the objective cognitive assessment, we selected a group of 
neuropsychological instruments that had been used to measure various components of 
executive functions.  
1.2.2.1. Phonological Fluency 
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We used a phonological verbal fluency test that measured the spontaneous production 
of words beginning with the letters P, M and R within a time limit of 60 seconds for 
each letter. This provided information about the ability of the updating function. Proper 
nouns, repetitions and variations were not admitted. In the original English language 
version of this test, F, A, and S were the letters most commonly used, but in the Spanish 
version, the letters P, M and R are used [36]. The score was the sum of all the 
admissible words. 
1.2.2.2. Paced Auditory Serial Addition Task (PASAT) 
This is another test which assesses working memory, but also sustained attention, 
auditory processing speed, calculation ability and stimulus competition filtering skill 
[37]. The subjects added up consecutive numbers ranging from 1 to 9 presented by an 
auditory tape and responded orally by giving their sum. As each digit was presented, the 
patients added this number to the one presented before it. The presentation rates were 
3.0 seconds in trial 1 (PASAT 3.0) and 2.0 seconds in trial 2 (PASAT 2.0). The score 
for each trial was given by the number of correct responses to 60 different 
combinations. 
1.2.2.3. N-back Paradigm.  
This task assesses working memory and requires relevant pieces of information 
to be maintained and constantly updated. It was performed with the aid of a computer 
and the subjects were required to monitor a continuous sequence of digits and to 
respond whenever the stimulus presented was the same as the one presented in previous 
trials, in which n was either 2 (2-back condition) or 3 (3-back condition) [38]. The 
participants were instructed to respond to the correct answer as quickly and accurately 
as possible by pressing the computer spacebar key.  Each trial consisted of a stimulus, 
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which was presented for 500 milliseconds, followed by an interstimulus interval of 1500 
milliseconds. After this period, the next stimulus was presented. In each block, a series 
of black numbers, ranging from zero to nine, were randomly presented in the centre of a 
grey background. There were 30 stimuli within each condition, 6 of which were the 
correct targets. Each block consisted of a 2-back condition followed by a 3-back 
condition, with each one being presented three times. The outcomes were the total 
number of correct responses for each condition.  
1.2.2.4. Trail Making Test 
 The Trail Making Test is a set of visual search and sequencing tasks involving 
motor speed, attention and the ability to alternate between categories (set-shifting) [39]. 
In TMT-A, subjects were asked to connect consecutive numbers (e.g., 1-2-3), whereas 
in TMT-B, they had to alternate between consecutive numbers and letters (e.g., 1-A-2-
B). The scores were based on the amount of time taken to complete each part of the test. 
We were specifically interested in evaluating the set-shifting ability and to do this we 
calculated a derived score based on the difference between the score TMT-B and TMT-
A scores. 
1.2.2.5.  Stroop Color and Word  Test  
The Stroop Color and Word Test [40] was used to assess interference inhibition 
ability. The test consists of using a Word Card with 100 colour words (red, blue and 
green) printed in black ink, a Colour Card with 100 Xs printed in blue, red or green ink, 
and a Colour–Word Card with 100 names of colours printed in incongruent colours. 
Participants are asked to read the words (on the Word Card) or to name the ink colour 
(on the Colour Card and Colour-Word Card), as quickly as possible and within a time 
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limit of 45 seconds. We assessed the inhibition ability by calculating the interference 
effect as the number of correct responses given in the Colour-Word Card test minus the 
number of correct responses in the Colour Card test.  
 2.2.2.6. Wisconsin Card Sorting Test 
 The computerized version of the Wisconsin Card Sorting Test-64 [41,42] was 
used to assess abstract reasoning and the ability to change cognitive strategies in 
response to changing environmental contingencies. The participants were asked to sort a 
series of cards bearing simple stimuli that were characterized by three relevant 
categories (colour form, and number) and to relate them to four reference cards. The 
rules for correctly sorting the cards were modified during the test (every time that the 
participant achieved 10 consecutive hits in a certain category). We used the total 
number of categories achieved as a measure of abstract reasoning and the total number 
of perseverative errors as a measure of cognitive flexibility. The number of categories 
achieved corresponded to the number of runs of 10 correct responses and the number of 
perseverative errors was given by the total number of times that the subject failed to 
change their sorting strategy after receiving negative feedback.  
2.2.2.7. WAIS-III-R Vocabulary subtest  
 We used the scaled score from the vocabulary subtest of the Weschler-III scale 
[34] as a measure of premorbid intelligence. The participants were required to provide 
definitions of words presented in order of increasing difficulty. 
 
1.2.3. Mood Assessment 
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 The Spanish version of the Beck Depression Inventory (second edition: BDI-II) 
[43,44] was used to assess the intensity of depressive symptoms. The BDI-II consists of 
21 items that assess emotional, behavioral and somatic symptoms associated with 
depression. In this test, the scores range from 0 to 63, with higher scores indicating 
greater depressive symptoms.  
 The Spanish version of the State-Trait Anxiety Inventory (STAI) [45,46], was 
used to evaluate the intensity of anxiety. This consists of two subscales, each composed 
of 20 items. The State subscale measures anxiety related to a specific situation or time-
period (at the moment of questionnaire completion), while the Trait subscale measures 
relatively stable anxiety. The total scores range from 20 to 80 for each subscale, with 
higher scores indicating greater levels of anxiety. 
 
2.3. Statistical Analysis 
We used the SPSS 16 program for Windows (SPSS Inc.) to perform our statistical 
analyses. We analysed whether there were differences between the two groups in terms 
of age, years of education, premorbid intelligence and mood disturbances, using the 
Student's t test. We used multivariate analysis of variance (MANOVA) to establish the 
presence or absence of differences between the 2 groups for the BRIEF-A scale and also 
in the cognitive tests. We subsequently performed post-hoc univariate analysis and 
measured the size of the effect using the eta-squared coefficient (η2), in which values of 
>0.01, >0.06 and >0.14 were respectively defined as small, medium and large. We then 
repeated the multivariate analyses using BDI-II and STAI scores as covariates.  
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For the cognitive measures, we calculated standard normal Z-scores for fibromyalgia 
patient data based on our own control data and averaged these Z-scores to obtain the 
level of impairment. Individual Z-scores were calculated by the following formula: Z = 
(valuepatient-meancontrols/SDcontrols). The BRIEF-A scores were converted into T scores, 
and T scores ≥65 were considered clinically elevated [26]. Then, we calculated the 
percentage of participants in each group who presented clinically elevated scores for 
this measure. We also used the Fisher’s Exact Test to compare the results obtained for 
the 2 groups. We computed Pearson correlations to analyse the associations between the 
BRIEF-A subscales and the cognitive tests, and between these measures and BDI-II and 
STAI. Statistical significance was declared at P <0.05. 
 
3. Results 
3.1. Sample characteristics 
There were no significant differences between the two groups in terms of age, years of 
education or premorbid intelligence. However, the 2 groups differed significantly in 
their scores on the BDI-II and STAI scales (p<0.001). The fibromyalgia patients 
exhibited higher scores on both scales, with a significant higher incidence of symptoms 
associated with depression and anxiety than the control group (Table 1).  
 
3.2. Inter-group analyses for BRIEF-A 
No subjects had elevated scores on the Infrequency and Inconsistency scales. The 
Negativity scale was elevated for 45 patients from the fibromyalgia group (54% of the 
patients in this group), whereas none of the control group showed elevated scores on 
this scale. The high scores registered on the Negativity scale for the fibromyalgia group 
may be related to the known negative response pattern of these patients, which is 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
associated with high psychiatric comorbidity rates, rather than to a lack of validity of 
their responses to this questionnaire. We found strong associations between the 
Negativity scale score and BDI-II (r=0.75, p<.001), STAI State (r=0.66, p<.001) and 
STAI Trait (r=0.66, p<.001). For all of these reasons and as none of the protocols 
produced elevated scores on any of the other validity scales, we chose to include these 
subjects in the subsequent statistical analyses.  
The overall MANOVA for the BRIEF-A subscales revealed significant differences 
between the fibromyalgia patients and the control group, with a Wilks λ=0.437, 
F(11.933), p<0.001, η2=0.56, showing greater dysfunction amongst the fibromyalgia 
patients. Adding the BDI-II and STAI scores as a covariate in the multivariate analysis 
attenuated the effect of size but did not change the overall pattern of the results 
obtained, with a Wilks λ=0.829 and F(1.843), p=0.05, η2=0.17. Within the MANOVA, 
the omnibus univariate tests were significant for the Working Memory subscale 
(p=0.002), Metacognition Index (p=0.036) and Global Executive Composite Index 
(p=0.037), with a medium effect size for the Working Memory subscale and a small 
effect size for the Metacognition and Global Executive Composite Index (Table 2). 
When we also considered age and education, in addition to BDI-II and STAI scores, as 
potentially confounding variables in the multivariate inter-group analysis, a borderline 
p-value was observed: Wilks λ=0.833 and F(1.758), p=0.065, which was attributable to 
the consequent unnecessary loss of statistical efficiency in the variability estimation. 
Even so, when we specifically considered individual subscales, the results obtained 
were similar in terms of their statistical significance. 
To further investigate the clinical context, we examined the percentage of individuals in 
each of the 2 groups who had clinically elevated scores: with T scores of 65 or more 
[26]. In the fibromyalgia group, more than half of the subjects exhibited clinically 
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elevated scores on six (Inhibit, Shift, Emotional Control, Initiate, Working Memory and 
Plan) of the nine subscales. In contrast, in the control group, the Plan subscale was the 
one that contained the highest proportion of subjects with clinically elevated scores 
(24%), while the other scales showed lower proportions (0-16.7%).  Comparisons 
between the 2 groups for the percentage of participants with clinically elevated scores 
revealed significant differences for all of the scales except that relating to Organization 
of Materials (Table 3). 
 
3.3. Inter-group analyses for the objective cognitive measures 
The MANOVA for the objective cognitive tests also revealed significant differences 
between the 2 groups (Wilks λ=0.751, F(3.895), p=<0.001, η2=0.249), although these 
disappeared after adjusting for the B I-II and STAI measures;  the overall MANOVA 
was non-significant (Wilks λ=0.841, F(1.357), p=0.19, η2=0.159). Despite the results of 
the MANOVA, we applied a univariate test to study each measure independently and to 
assess in more detail some of the measures which had previously been reported to have 
significant associations [7,47]. We only found significant differences between the 
groups for the interference effect from the Stroop Test, which exhibited a small size 
effect (p=0.03, η2=0.05 (Table 4).   
 
3.4. Associations between BRIEF-A and objective cognitive measures  
An analysis of the associations between scores for objective cognitive measures and 
BRIEF-A scale scores in the group of fibromyalgia patients showed a significant 
negative correlation for a 3-back test with several BRIEF-A scales; these included: 
Inhibit (r=-0.34, p=0.003), Shift (r=-0.26, p=0.03), Initiate (r=-0.23, p=0.04), Working 
memory (r=-0.28, p=0.009), and Plan scale (r=-0.25, p=0.03), as well as for the 
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Behavioral Regulation Index (r=-0.27, p=0.01) and Metacognition Index (r=-0.24, 
p=0.04). We also identified significant negative associations between the WCST-
categories score, an objective cognitive measure, and the Working Memory scale from 
BRIEF-A (r=-0.24, p=0.03) (Table 5). 
 
 
4. Discussion  
On examining executive functioning in patients with fibromyalgia using subjective self-
report measures and objective cognitive tests, we initially found significant differences 
with respect to the control group. Fibromyalgia patients generally exhibited worse 
levels of performance, although many of the differences appeared to be influenced by 
mood disturbances, since most of them disappeared after adjusting for depression and 
anxiety.  
 
  As expected, fibromyalgia patients exhibited higher scores than the control 
group for measurements of mood symptoms related to depression and anxiety. These 
results agree with the vast majority of studies undertaken with patients suffering from 
fibromyalgia; this would therefore seem to be a common feature in these patients [48–
51]. The influence of mood symptoms in subjective ratings of cognitive functioning has 
also been reported in other populations. This has occurred in both subjective measures 
of general cognitive functioning [52–55] and in subjective measures of executive 
performance using BRIEF-A, in which they were the strongest predictors of subjective 
executive dysfunction [56,57]. Our results also paralleled  those presented in the 
original validation of BRIEF-A, which reported a significant association between this 
scale and both the Beck Depression Inventory II and State-Trait Anxiety Inventory [26]. 
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 In the case of specific results relating to subjective measures, we found 
significant differences between groups for all of the BRIEF-A scales. This led us to 
conclude that these patients probably presented impaired executive functioning in their 
daily lives. However, when we wanted to separate the influence of mood on executive 
performance, we found that most of the perceived executive dysfunctions disappeared, 
leaving only differences between groups associated with the Working Memory Scale. 
As a result, these patients reported experiencing significant problems relating to this 
ability that were independent of the severity of their mood symptoms. These results 
were in line with those of several other neuroimaging studies and add to growing 
evidence that fibromyalgia patients tend to exhibit several abnormalities in their 
frontoparietal networks which, in turn, affect their working memory processes [58,59]. 
Functional impairment in these brain regions has also been widely associated with pain, 
anxiety and depression: symptoms that often occur together in people diagnosed with 
fibromyalgia [60–62].  
  
 The results for the objective cognitive tests were similar to those previously 
described, with there being significant differences between groups for all of the tests. 
The worst initial performances were associated with fibromyalgia patients, although 
most of the observed differences disappeared when we adjusted for depression and 
anxiety. In this case, once we had made adjustments for mood symptoms, the 
significantly worse performances by fibromyalgia patients only persisted for 
interference inhibition ability in the Stroop Test. No differences were identified between 
the other executive functions evaluated: updating, cognitive flexibility, working 
memory, abstract reasoning and shifting, once mood-related symptoms had been 
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isolated. These results were in line with those cited in recent publications on 
fibromyalgia and chronic pain by authors such as Cherry et al [47]. These authors also 
pointed to impairment of cognitive inhibition but not of either cognitive flexibility or 
verbal fluency in their sample of fibromyalgia patients, who were all assessed using 
objective cognitive measures. Glass et al [63], who used neuroimaging, also identified 
altered brain activity in response to a motor inhibition task in the group of patients with 
fibromyalgia. The study by Mercado et al [64] followed similar lines, with the authors 
reporting that fibromyalgia patients experienced specific problems of cognitive 
inhibition when they were assessed using an emotional Stroop task and event-related 
potentials. Finally, Berryman et al [65], who carried out a systematic review and made a 
meta-analysis of executive function in people with chronic pain, also found evidence of 
minor to moderate impairment in response inhibition.  
 
 The impaired cognitive inhibition mechanisms identified in the fibromyalgia 
patients was compatible with the hypothesis of hypervigilance to pain and to pain-
related information that has already been extensively described in this population. This 
points to the existence of an attentional bias toward negative information and to 
difficulties in inhibiting thoughts that prevent fibromyalgia patients from carrying out 
other daily tasks [66,67].  
 
 Our results failed to identify any significant differences between objective 
cognitive measures of working memory after adjusting for depression and anxiety. This 
was in line with some previous studies which revealed that mood could explain the 
observed cognitive impairment [10–12]. Even so, our results differed from others that 
had reported impairments in working memory in fibromyalgia patients assessed using 
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objective cognitive tests [6,68,69]. Such differences may, however, have been 
attributable to the different configurations of the samples used in the studies, given that 
depressive symptomatology was an exclusion criterion in some of them. This is 
particularly noteworthy considering that the severity of depression in our sample was 
moderate or even severe.  
 
Moreover, in the same way that we found some different results using subjective 
and objective measurements of executive functions, we also found a general lack of 
extensive significant associations between the two types of measures. The exception to 
this general tendency was the 3-back test, which correlated with several BRIEF-A 
scales and indices. The lack of extensive significant association between the two types 
of measures was expected and was in line with results obtained from several other 
studies; this would perhaps suggest that the subjective and objective measures could, in 
fact, measure different constructs [29,30,70]. In this regard, it should perhaps be added 
that several researchers have previously highlighted the fact that objective cognitive 
tests are designed to assess an isolated aspect of behavior, separating it from the 
influence that other variables might have on the same behavior. On the other hand, 
subjective measures, such as BRIEF-A, tend to evaluate the application of these skills in 
daily life, which often includes their interaction with an environment characterised by 
complex and multifactorial demands [25,71,72]. All of these results support the 
combined use of both types of measures to provide more comprehensive information 
about these patients. Special mention must also be made of the associations identified 
between the 3-back test and several BRIEF-A scales and indices. These may point to the 
3-back test being an objective cognitive task with a high cognitive load that probably 
does not only evaluate a single, isolated aspect of working memory, but also the 
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inhibition, shift, initiation and planning abilities measured by BRIEF-A. In this regard, 
similar results were found by Garcia-Molina et al [20] in a study that was conducted 
with a group of individuals with moderate-to-severe TBI. They identified a limited 
number of associations between BRIEF-A and objective cognitive measures. The 
exception to this general situation was found with the Letter-Number Sequencing test, a 
working memory measure which correlated with many of the BRIEF-A scales and 
indices. More research is clearly needed in this area in order to elucidate the relations 
between objective cognitive measures of working memory and the different BRIEF-A 
scales. 
 
 Regardless of the possible reasons for the impairment of executive performance, 
we were also interested in knowing the clinical relevance of the perceived functioning 
in our sample and analysed the percentage of individuals in each group who reported 
clinically elevated BRIEF-A scores. In this case, we found that the clinical impact was 
significant. It revealed considerable differences between groups, with more than half of 
the fibromyalgia patients having experienced problems with: their control impulses 
(Inhibit scale); their ability to think flexibly and/or to accept different ways of solving 
problems (Shift scale); their ability to modulate emotional responses appropriately 
(Emotional Control scale); their ability to start tasks and/or to create problem-solving 
strategies (Initiative scale); their ability to hold in mind and simultaneously manipulate 
information (Working Memory scale); and their ability to anticipate future events and 
set goals (Plan scale). These results should be taken into account, because they 
demonstrate that fibromyalgia patients experience all of these problems in their daily 
lives and that it is very difficult to dissociate them from their mood. This perceived 
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executive dysfunction would also probably have an impact on their social, occupational 
and emotional performances, which would include poorer treatment adherence. 
 
 Several of the current limitations of this study need to be addressed. First, it may 
include a potential selection bias, given that it was not possible to randomise the 
selection of participants. Instead, it was the subjects themselves who decided whether or 
not to participate in the study. It is, however, worth mentioning that refusal to 
participate in the study was minimal, both amongst patients and members of the control 
groups. Further, there was similarly only a minor loss of cases during the assessment 
process. The high presence of depressive and anxiety symptoms in the group of 
fibromyalgia patients was also a limiting factor in this study, given its observational 
nature. Even so, we consider that it probably provides a faithful reflection of the current 
reality of fibromyalgia patients. However, for this reason, we would propose larger 
observational studies that should also include fibromyalgia patients who are not 
suffering from depression. Another limitation may be the high proportion of 
fibromyalgia patients with high scores in the Negativity scale of BRIEF-A, which was 
one of the three validity scales for this measure. However, as that none of the subjects 
scored highly on the other validity scales, we related the high level of negativity to the 
severity of the depressive symptoms reported by many fibromyalgia patients. Another 
limitation worth highlighting was the lack of control over the medication that the 
patients were taking. Although we excluded patients who were taking antipsychotic 
medication, others receiving treatment with anxiolytic agents and antidepressants were 
included in the study. It is, however, important to note that when patients were receiving 
treatments including anxiolytics, these were only administered at low doses. Finally, it 
must be underlined that this study has not included in its analysis the influence of other 
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relevant symptoms of fibromyalgia, such as the degree of pain, fatigue or sleep disorder, 
all of which can also affect cognitive functions. These factors should also be considered 
in future studies. 
 
5. Conclusions 
Using a combination of subjective and objective measures, we found that 
patients with fibromyalgia showed impairment in some components of their executive 
functions. The main functions affected were working memory and inhibition, and the 
effects noted could not be explained by mood. We would argue that subjective and 
objective measures can provide useful and complementary information to help us 
understand the scope of the executive dysfunction often exhibited by these patients. 
Mood disturbances, which tend to be very frequent in this disease, contribute to a 
worsening of the global executive dysfunction suffered by these patients and have a 
negative impact on their daily functioning. These results underscore the need to design 
and implement clinical interventions to address impaired cognitive functioning in these 
patients and to intervene on both the cognitive and mood levels in order to improve their 
functionality.  
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Table 1. Demographic and Clinical Characteristics for patients with fibromyalgia and 
controls  
 
Fibromyalgia 
Patients 
(n=82) 
Controls                  
(n = 42) 
p  
 
 
M SD M SD 
 
Age (years) 45.24 5.31 45.88 6.30 .55 
Education (years) 10.39 
 
2.72 11.17 2.70 .13 
WAIS-III Vocabulary
1
 10.48 3.70 11.21 1.60 .22 
BDI-II 24.93 12.05 5.45 5.65 <.001 
STAI State 36.55 11.26 16.59 9.19 <.001 
STAI Trait 35.48 11.11 12.54 8.201 <.001 
Notes. WAIS-III = Wechsler Adult Intelligence Scale 3r version; BDI-II = Beck 
Depression Inventory-II; STAI = State-Trait Anxiety Inventory 
 1
Data are presented in mean scaled scores.  
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Table 2. Means, standard deviations and group differences on BRIEF-A adjusted for 
BDI-II and STAI State and Trait scores 
BRIEF-A Subscales 
Fibromyalgia 
Patients       
(n=82) 
Controls 
(n = 42) p 
 
η2 
 
M SD M SD 
Inhibit 60.9 10.01 47.0 6.17 .17 .01 
Shift 67.8 11.83 52.5 9,83 .56 .003 
Emotional Control 68.2 12.25 54.2 11.25 .50 .004 
Self-Monitor 59.13 11.70 51.1 9.31 .70 .001 
Initiate 67.7 10.50 48.5 9.34 .07 .02 
Working Memory 73.0 11.57 51.4 11.61 .002 .07 
Plan/Organize 71.4 10.87 57.5 10.46 .77 .001 
Task Monitor 52.9 9.09 43.9 6.96 .89 .000 
Organization of Materials 53.7 11.82 46.9 9.03 .89 .000 
Behavior Regulation Index 67.5 10.92 51.7 8.90 .49 .004 
Metacognition Index 68.15 11.13 49.8 9.17 .03 .04 
Global Executive Composite 68.7 10.10 50.2 8.65 .03 .04 
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Table 3. Prevalence rate comparisons for the percentage of individuals with clinically 
elevated BRIEF-A scores  
BRIEF-A Subscales 
Fibromyalgia 
Patients 
(n=82) 
Healthy 
Controls 
(n = 42) 
p 
Inhibit  35.7 2.4 <.001 
Shift 63.1 16.7 <.001 
Emotional Control 60.7 16.7 <.001 
Self-Monitor 23.8 4.8 .005 
Initiate 60.7 4.8 <.001 
Working Memory 76.2 16.7 <.001 
Plan/Organize 71.4 23.8 <.001 
Task Monitor 13.1 0 .009 
Organization of Materials 13.1 7.1 .24 
Behavior Regulation Index 61.9 7.1 <.001 
Metacognition Index 57.14 4.76 <.001 
Global Executive Composite 59.52 2.38 <.001 
Notes. Clinically elevated BRIEF-A score = T-scores ≥65 [26] 
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Table 4. Z scores and group differences on neuropsychological measures adjusted for 
BDI-II score and STAI-State and Trait scores 
 
Fibromyalgia 
Patients       
(n=84) 
Controls 
(n = 42) p η2 
m SD m SD 
z  PMR - .37 .74 - .006 .96 .37 .007 
z  PASAT 3.0 -1.09 1.72 .07 .99 .09 .03 
z  PASAT 2.0 -1.05 1.70 .04 .97 .16 .02 
z  2-back -.81 1.60 -.002 1.01 .54 .003 
z  3-back -.55 1.07 .03 .98 .45 .005 
z  TMT B-A .11 .64 -.01 1.01 .80 .001 
z  SCWT, Interference Task  -.60 .64 -.01 1.01 .03 .05 
z  WCST categories 1.44 8.35 -.008 1.01 .18 .02 
z  WCST persev. responses .22 .96 -.01 1.01 .98 .000 
Notes: PMR = Phonemic verbal fluency test; PASAT3 = Paced Auditory Serial 
Addition Test version 3; PASAT2 = Paced Auditory Serial Addition Test version 2; 
TMTB-A = Trail Making Test, total difference part B minus part A; SCWT, Stroop 
Word and Color Test; WCST categories = Wisconsin Card Sorting Test, total categories 
accomplished; WCST perserv responses = Wisconsin Card Sorting Test, total 
perseverative responses 
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Table 5. Spearman correlations between BRIEF-A scales and neuropsychological 
measures for Fibromyalgia Patients 
 PMR 
PASAT 
3.0 
PASAT 
2.0 
2-back 3-back 
TMT 
B-A 
SCWT 
Interf. T.  
WCST 
categ 
WCST 
per resp 
Inhibit .01 .00 .01 .22 -.337** .15 .10 -.15 -.13 
Shift -.13 -.15 -.07 -.19 -.251* .12 .06 -.17 -.02 
Emotional Control -.05 -.01 .04 -.06 -.14 -.01 -.09 -.06 -.05 
Self-Monitor -.06 .05 .07 -.12 -.12 -.04 .02 -.08 -.05 
Initiate -.17 -.08 -.07 -.18 -.233* .15 .03 -.14 .17 
Working Memory -.12 -.09 -.05 -.18 -.295** .07 .00 -.245* -.01 
Plan/Organize -.15 -.04 -.03 -.19 -.248* .00 .00 -.15 .00 
Task Monitor .13 -.01 .04 .08 -.09 .00 .07 -.11 .07 
Organization of Mat. .04 .08 .08 .13 .05 -.09 .08 -.11 -.04 
Behavior Regulation I. -.11 -.08 -.05 -.20 -.268* .09 -.03 -.15 -.05 
Metacognition Index -.01 -.11 -.05 -.09 -.236* .17 -.03 -.22 .06 
Global Exec Comp. -.12 -.01 .00 -.12 -.18 .03 .01 -.20 .01 
Notes: PMR = Phonemic verbal fluency test; PASAT3 = Paced Auditory Serial 
Addition Test version 3; PASAT2 = Paced Auditory Serial Addition Test version 2; 
TMTB-A = Trail Making Test, total difference part B minus part A; SCWT Interf. T. = 
Stroop Word and Color Test, Interference Task; WCST categ = Wisconsin Card Sorting 
Test, total categories accomplished; WCST per resp = Wisconsin Card Sorting Test, 
total perseverative responses  
* p < .05 
** p < .001 
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Table 6. Spearman correlations between BRIEF-A scales and neuropsychological 
measures for Controls 
 PMR 
PASAT 
3.0 
PASAT 
2.0 
2-back 3-back 
TMT 
B-A 
 SCWT 
Interf. T 
WCST 
categ 
WCST 
per resp 
Inhibit -.21 -.33* -.28 .73 -.11 -.02 -.03 -.35* .05 
Shift -.06 -.02 -.12 -.05 -.16 .28 -.05 -.21 .11 
Emotional Control -.05 .03 -.05 .14 -.02 .04 .00 -.27 -.05 
Self-Monitor -.01 -.19 -.28 .05 -.12 .23 .02 -.19 .18 
Initiate -.09 -.08 -.19 .17 -.07 .15 .14 -02 .27 
Working Memory -.27 .02 -.09 .06 -.08 .23 .13 -.13 .14 
Plan/Organize -.08 -.28 -.14 .04 -.03 .29 .04 -.15 .10 
Task Monitor -.09 -.15 -.21 .11 -.12 -.02 .27 -.28 .31* 
Organization of Mat. -.19 -.37* -.28 .03 -.22 .19 .25 -.07 .15 
Behavior Regulation I. -.09 -.08 -.22 .10 -.04 .15 .18 -.27 .11 
Metacognition Index -.16 -.16 -.22 .06 -.08 .21 .23 -.25 .31* 
Global Exec Comp. -.19 -.18 -.23 .05 -.17 .24 .12 -.29 .16 
* p < .05 
